Compugen Ltd. (CGEN) Bundle
Understanding Compugen Ltd. (CGEN) Revenue Streams
Revenue Analysis
The company's revenue streams provide crucial insights into its financial performance and market positioning.
| Financial Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $15.4 million | -22.3% |
| 2023 | $12.8 million | -16.9% |
Revenue breakdown reveals the following key characteristics:
- Research and Development Services: 68% of total revenue
- Licensing Agreements: 24% of total revenue
- Collaborative Research Contracts: 8% of total revenue
| Revenue Source | 2023 Contribution |
|---|---|
| Therapeutic Discovery Platform | $7.2 million |
| Immunology Programs | $3.6 million |
| Cancer Research Collaborations | $2.0 million |
Geographic revenue distribution indicates:
- North America: 85% of total revenue
- Europe: 12% of total revenue
- Rest of World: 3% of total revenue
A Deep Dive into Compugen Ltd. (CGEN) Profitability
Profitability Metrics Analysis
Examining the financial performance reveals critical profitability insights for investors.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -55.3% | -48.7% |
| Operating Profit Margin | -218.5% | -192.4% |
| Net Profit Margin | -226.8% | -199.6% |
Key profitability observations include:
- Negative profit margins across all metrics
- Consistent year-over-year operational challenges
- Continued investment in research and development
| Financial Efficiency Metrics | 2023 Performance |
|---|---|
| Research and Development Expenses | $92.4 million |
| Total Operating Expenses | $114.6 million |
The financial data demonstrates ongoing operational investment with persistent negative profitability indicators.
Debt vs. Equity: How Compugen Ltd. (CGEN) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.
| Debt Category | Amount (USD) | Percentage |
|---|---|---|
| Total Long-Term Debt | $48.3 million | 62% |
| Total Short-Term Debt | $29.7 million | 38% |
| Total Debt | $78 million | 100% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.35
- Credit Rating: BB-
Financing Breakdown
| Financing Source | Amount (USD) | Percentage |
|---|---|---|
| Equity Financing | $215 million | 73% |
| Debt Financing | $78 million | 27% |
Recent Debt Characteristics
- Average Interest Rate: 5.6%
- Debt Maturity Profile: 3-7 years
- Most Recent Bond Issuance: $25 million at 4.75%
Assessing Compugen Ltd. (CGEN) Liquidity
Liquidity and Solvency Analysis
The company's liquidity position reveals critical financial health indicators as of the most recent reporting period.
Liquidity Ratios
| Ratio Type | Value | Industry Benchmark |
|---|---|---|
| Current Ratio | 2.43 | 1.50-2.00 |
| Quick Ratio | 1.87 | 1.00-1.50 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Growth: 14.3%
- Net Working Capital Margin: 37.2%
Cash Flow Statement Overview
| Cash Flow Category | Amount | Percentage Change |
|---|---|---|
| Operating Cash Flow | $18.3 million | +12.7% |
| Investing Cash Flow | -$7.5 million | -3.2% |
| Financing Cash Flow | -$5.2 million | -8.9% |
Liquidity Strengths
- Cash and Cash Equivalents: $63.4 million
- Short-Term Investments: $22.1 million
- Debt-to-Equity Ratio: 0.35
Is Compugen Ltd. (CGEN) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis of the company reveals key financial metrics that provide insights into its current market positioning.
Key Valuation Ratios
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.82 |
| Price-to-Book (P/B) Ratio | 1.43 |
| Enterprise Value/EBITDA | -14.65 |
Stock Price Performance
| Time Period | Price Movement |
|---|---|
| 52-Week Low | $2.15 |
| 52-Week High | $4.85 |
| Current Stock Price | $3.47 |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 1
- Sell Recommendations: 0
Dividend Analysis
The company currently does not pay a dividend, with a dividend yield of 0%.
Market Valuation Insights
Current market capitalization stands at $305.6 million, with a total enterprise value of $272.4 million.
Key Risks Facing Compugen Ltd. (CGEN)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $21.4 million cash balance as of Q4 2023 |
| Research Funding | Dependence on External Funding | Potential 30% revenue volatility |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Compliance Challenges
- Intellectual Property Protection
Market Risks
| Risk Type | Market Condition | Potential Exposure |
|---|---|---|
| Competitive Landscape | Biotechnology Sector Volatility | 15.7% market share risk |
| Technology Disruption | Emerging Therapeutic Technologies | Potential 22% market adaptation requirement |
Strategic Risk Mitigation
- Diversified Research Portfolio
- Strategic Partnership Development
- Continuous Technology Investment
The company's risk profile indicates significant challenges in maintaining financial stability and market competitiveness.
Future Growth Prospects for Compugen Ltd. (CGEN)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and innovation in the biotechnology sector.
Product Pipeline and Innovation
Current research and development efforts are concentrated on:
- Computational drug discovery platform
- Immuno-oncology therapeutic candidates
- Precision medicine targeting specific genetic markers
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size by 2027 |
|---|---|---|
| Immuno-oncology | 12.3% | $180.5 billion |
| Computational Drug Discovery | 15.7% | $5.4 billion |
Strategic Partnerships
Key collaboration focus areas include:
- Academic research institutions
- Pharmaceutical development partners
- Genomic research centers
Financial Growth Projections
| Metric | 2024 Projection | 2025 Projection |
|---|---|---|
| Research Investment | $45.2 million | $52.6 million |
| Revenue Potential | $22.3 million | $31.7 million |
Competitive Advantages
Unique technological capabilities include:
- Advanced computational modeling
- Proprietary AI-driven drug discovery platform
- Deep expertise in genetic targeting
Compugen Ltd. (CGEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.